

Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry

Charles D. Burger, MD; Pamela K. Long, RN; Monarch R. Shah, MS; Michael D. McGoon, MD; Dave P. Miller, MS; Alain J. Romero, PharmD, PhD; Wade W. Benton, PharmD; Robert E. Safford, MD, PhD

CHEST 2014; 146(5):1263-1273

e-Table 1. IRB Committee and project approval number list.

Study Center	Name of IRB	Approval Number
Intermountain Medical Center	Intermountain Healthcare Urban Central Region IRB	1009009
Allegheny General Hospital	ASRI- WPAHS Institutional Review Board	RC-4088
University of Pittsburgh Medical Center Cardiovascular Institute	WIRB	1077291
Oregon Health and Science University (up to 06Jun2008)	Oregon Health and Science Univeristy IRB	IRB00002436
Legacy Good Samaritan Hospital and Health Center (after 06Jun2008)	WIRB	1099977
Inova Fairfax Hospital	WIRB	1079519
Kalamazoo Center for Medical Studies	Spectrum Health IRB	2006-108
University of Colorado Health Sciences Center	Colorado Multiple Institutional Review Board	06-0235
Mayo Clinic Rochester	Mayo Clinic Office for Human Research IRB	06-002271

Online supplements are not copyedited prior to posting.



Baylor College of Medicine	Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals	H-19065
Midwest Heart Specialists	WIRB	1078500
Georgia Health Sciences University	Human Assurance Committee	06-05-288
Aurora St. Luke's Medical Center	Aurora IRB	L-06-74E
University of Alabama at Birmingham	WIRB	1078385
The University of Texas Health Science Center at San Antonio	The University of Texas Health Science Center IRB	HSC20070383H
University of Iowa Hospital and Clinics	Human Subjects Office/ Institutional Review Board/ Hawk IRB	200603714
University of Colorado School of Medicine	Colorado Multiple Institutional Review Board	06-0500
University of California, San Diego	UCSD Human Research Protections Programs	060466
Ochsner Clinic Foundation	Ochsner Clinic Foundation IRB	2006.085.B
Rhode Island Hospital	Lifespan Rhode Island IRB	4075-06
University of Maryland	University of Maryland IRB	H-28017
Temple University	Temple University IRB	10127
Brigham and Women's Hospital	Brigham Women's Hospital IRB	2006-P-000884/1
Mayo Clinic Florida	Mayo Clinic Office for Human Research IRB	06-002271
University of California San Francisco	Human Research Protection Program	10-00632

Online supplements are not copyedited prior to posting.



North Shore- Long Island Jewish Health Systems	BRANY IRB	06-02-83-03
VA Greater Los Angeles Healthcare System	VA Greater Los Angeles Healthcare Systems IRB	2006-060912
University of Rochester	University of Rochester Research Subjects Review Board	RSRB00014458
Washington University in St. Louis	Washington University Human Research Protection Office	06-0753
Suncoast Lung Center	WIRB	1080843
Wayne State University	Wayne State University IRB	0606003802
Duke University Medical Center	Duke University Health System IRB	Pro00008240
University of Pennsylvania	University of Pennsylvania IRB	804760
University of Arizona	University of Arizona Human Subjects Protection Program	BSC B06.231
University of Minnesota Medical Center	University of Minnesota Research Subjects' Protection Programs IRB	0607M89066
Boston University Medical Center	WIRB	1081775
Nationwide Children's Hospital	Nationwide Children's Hospital IRB	IRB10-00475
Johns Hopkins University	WIRB	1078595
Cleveland Clinic	Cleveland Clinic Foundation IRB	06-259
Columbia University Medical Center	Columbia University Medical Center IRB	AAAC0789
University of Chicago	The University of Chicago AURA IRB	14917B
Medical University of South Carolina	The Medical University of South Carolina IRB for Human Research	16617

Online supplements are not copyedited prior to posting.



Texas Children's Hospital	Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals	H-19569
Tufts- New England Medical Center Hospital	Tufts Health Sciences Campus Institutional Review Board	7929
Lexington Pulmonary and Critical Care	WIRB	1085453
Stanford University Medical Center	Stanford University IRB	96981 / 5359
Monroe Carell Jr. Children's Hospital	Vanderbilt University IRB	061152
Vanderbilt Medical Center	Vanderbilt University IRB	070020
Ohio State University	Ohio State University Biomedical Sciences IRB	2006H0177
Kentuckiana Pulmonary Associates	WIRB	1086454
UCLA	UCLA Medical IRB	06-06-118-01
University Hospitals of Cleveland	University Hospitals Case Medical Center (UHCMC) IRB for Human Investigation	07-06-28
Beth Israel Medical Center	Beth Israel Medical Center IRB	013-08 / 132-10
Harbor UCLA Medical Center	Los Angeles Biomedical Research Institution	12722-01
Seattle Children's Hospital	Children's Hospital and Regional Medical Center Seattle, Washington IRB	06-0822
Virginia Commonwealth University	WIRB	1090150
University of Florida	WIRB	1097909

Online supplements are not copyedited prior to posting.

e-Table 2. No. (%) of first hospitalizations, by year post-enrollment.


	PAH related (n = 257)	PAH unrelated (n = 214)
First year post-enrollment, n (%)	145 (56.4)	104 (48.6)
Second year post-enrollment, n (%)	56 (21.8)	40 (18.7)
Third year post-enrollment or later, n (%)	56 (21.8)	70 (32.7)

PAH, pulmonary arterial hypertension.

Online supplements are not copyedited prior to posting.


e-Figure 1. Timing and type of PAH-related hospitalizations. (A) Proportion of intravenous line-related, right heart-related, or not specified hospitalizations occurring in each time period. (B) Proportion of PAH-related hospitalizations occurring in each time period for intravenous line-related, right heart-related, and not specified causes. Intravenous line-related hospitalizations included hospitalizations for initial intravenous line insertion, intravenous line conversion, placement or removal of a central venous catheter, right-heart catheterization, and catheter infection. Right heart-related hospitalizations included hospitalizations for congestive heart failure, syncope, PH medication-related adverse event, organ transplant, atrial septostomy, and escalation of PAH-related treatment. Not specified causes included all PAH-related but otherwise uncharacterized reasons.

e-Figure 1A.



Online supplements are not copyedited prior to posting.


e-Figure 1B.



Online supplements are not copyedited prior to posting.


e-Figure 2. Distribution of (A) intravenous line-related reasons and (B) right heart-related reasons for first-time hospitalization by time of event, as a proportion of the total number of reasons for hospitalization. Patients could have had more than one reason for hospitalization: in the first 6 months, 116 reasons were recorded for 100 patient admissions; in the second 6 months, 53 reasons were recorded for 45 patient admissions; in the second year, 62 reasons were recorded for 56 patient admissions; and in the third year or later, 62 reasons were recorded for 56 patient admissions. PAH-related, but otherwise uncharacterized, reasons for hospitalization are not shown, but they are counted in the total number of reasons for hospitalization. Uncharacterized PAH-related reasons were cited in 16 (13.8%) hospitalizations in the first 6 months, in 8 (15.1%) hospitalizations in the second 6 months, 9 (14.5%) hospitalizations in the second year, and 9 (14.5%) hospitalizations in the third year or later.

e-Figure 2A.



Online supplements are not copyedited prior to posting.

e-Figure 2B.



Online supplements are not copyedited prior to posting.